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Desensitization strategies for ABO-incompatible renal transplants with plasma exchange (PE) or speciﬁc immunoadsorption
(IA) decrease immunoglobulin levels. After recent measles outbreak and decreasing vaccination rates, we studied the impact
of apheresis on anti-measles antibodies. Anti-measles antibodies were measured before desensitization, before transplantation
and during followup in 12 patients with ABO incompatibility (2x PE only, 8x IA only, and 2x IA and PE) and 3 patients with
donor-speciﬁc HLA antibodies (all PE). Patients received rituximab, IVIG, and standard immunosuppressive therapy. All patients
had detectable anti-measles antibodies before desensitization (mean 3238mU/l, range 560–8100). After 3–6 PE sessions, titers
decreased signiﬁcantly to 1710mU/l (P<0.05), in one patient to nondetectable values, while IA only maintained protective titers.
After a median followup of 64 days, anti-measles antibodies returned to baseline in all patients. Immunity against measles was
temporarily reduced by apheresis but remained detectable in most patients at time of transplantation. Desensitization maintains
long-term protective immunity against measles.
1.Introduction
Desensitization protocols have been successfully implement-
ed worldwide for removal of donor-speciﬁc blood group or
HLA antibodies in the recipient to allow transplantations
across blood group and HLA barriers. Although there is
a high variability within these protocols, results for ABO-
incompatible transplantations are comparable to those used
for ABO-compatible transplantations regarding patient and
graft survival worldwide [1–8].
Current therapeutic apheresis techniques to remove
blood group antibodies include plasma exchange, double-
ﬁltration apheresis, protein A immunoadsorption, and an-
tigen-speciﬁc immunoadsorption (Glycosorb). Except for
the latter, these techniques are also suitable for removal of
HLA antibodies [9]. More selective methods have the ad-
vantage that large plasma volumes can be processed with
increasedeﬃcacy,butwithoutremovalofcoagulationfactors
and need for replacement ﬂuids. However, other donor-
speciﬁcantibodies,suchasHLAantibodies,arenotremoved,
and removal of complement factors may oﬀer additional ad-
vantages. Both can be achieved by “unspeciﬁc” plasma ex-
change, which is the most common technique used world-
wide due to availability.
With decreasing speciﬁcity, these regimens also result in
increasing removal of protective immunoglobulins resulting
from previous diseases or speciﬁc vaccinations. At present,
there is limited evidence that immunity to vaccinations
with antigens which readily elicit an immune response such
as tetanus toxoid is maintained after any of the above2 Journal of Transplantation
desensitization protocols. However, the eﬀects on immune
responses from vaccines with weaker antigens are far less
clear. In this respect, especially the protective eﬀects from
vaccinations with live vaccines appear of interest as such
vaccinations are contraindicated after solid organ transplan-
tation.Furthermore,recentoutbreaksofmeaslesinGermany
have raised the question, if a decreasing performance of vac-
cination and lower herd immunity in the population pose a
risk for measles infection in immunocompromised patients
after kidney transplantation, especially in view of new and
more intensive treatment strategies using apheresis tech-
niques. Therefore, we studied the eﬀect of various desensi-
tization protocols on anti-measles antibodies.
2.MaterialsandMethods
2.1. Patients. Between March 2007 and April 2011, at our
kidney transplant center, 17 patients were successfully trans-
planted after desensitization for ABO or HLA incompati-
bility. Two patients had to be excluded from this analysis
because of incomplete data. All patients gave informed con-
sent for participation in the study.
2.2. ABO-Incompatible Transplantation. All 12 patients with
ABO incompatibility received living donor kidney trans-
plants and had a negative complement-dependent cytotoxic
T-cell crossmatch. The desensitization protocol was adopted
according to previously published work [7, 8]. Brieﬂy,
rituximab (375mg/m2)w a sgi v e n∼4 weeks before the antic-
ipated transplantation. Triple oral immunosuppression with
tacrolimus, mycophenolate mofetil, and prednisolone or
methylprednisolone was started with initiation of apheresis.
Induction therapy was performed with basiliximab (day of
surgery and postoperative day 4) or antithymocyte globulin
(1 to 3 doses). Intravenous immunoglobulin (0.5g/kg)
was only given in the ﬁrst and second patients 4 days
before surgery and thereafter omitted from the protocol.
CMV prophylaxis with CMVIg was only given in the ﬁrst
patient postoperatively. All other patients received antiviral
prophylaxis with valganciclovir and cotrimoxazole for 3 to 6
months.
For removal of blood group antibodies, plasma exchange
or antigen-speciﬁc immunoadsorption was used. During
each plasma exchange, one-plasma volume was replaced
with 5 percent serum albumin, on the day of surgery or
immediately after surgery replacement consisting of 5 per-
cent human albumin and one liter of fresh frozen plasma.
Antigen-speciﬁc immunoadsorption was performed using
an antigen-speciﬁc carbohydrate column (Glycosorb A/B,
Glycorex Transplantation AB, Sweden). During each ses-
sion, 2-3 plasma volumes were processed. In two patients
only plasma exchange and in eight patients only antigen-
speciﬁc immunoadsorption was performed. In another two
patients, isoagglutinin titer reduction was not successful
using antigen-speciﬁc immunoadsorption, and therefore
plasma exchange was added. Apheresis was performed until
anti-A/B IgG isoagglutinin titers were 1:4 or less on the day
of surgery. Postoperative apheresis was only performed when
the anti-A/B IgG isoagglutinin titers exceeded 1:8 in the ﬁrst
week and 1:16 in the second week after surgery.
2.3. HLA-Incompatible Transplantation. Three patients re-
ceived desensitization therapy because of the presence of
donor-speciﬁc HLA antibodies in the presence of a negative
complement-dependent cytotoxic T-cell crossmatch. In two
patients,livingdonorkidneytransplantationwasperformed,
while in one patient cadaveric kidney transplantation was
performed after reduction of HLA antibodies. Rituximab
(375mg/m2) was given 4 weeks before the anticipated
transplantation or in the latter patient at time of trans-
plantation. A single dose of intravenous immunoglobulin
(1g/kg) was applied one week after the rituximab, that is,
before the start of plasma exchange. Triple oral immuno-
suppression with tacrolimus, mycophenolate mofetil, and
prednisolone/methylprednisolone was started with initia-
tion of apheresis. Induction therapy was performed with
basiliximab (day of surgery and postoperative day 4) or
antithymocyte globulin (2 doses). CMV prophylaxis with
CMVIgwasgiveninonepatientpostoperatively(patient15).
Allpatientsreceivedantiviralprophylaxiswithvalganciclovir
and cotrimoxazole for 3 to 6 months.
Plasma exchange was performed with one-plasma vol-
ume replaced by 5 percent serum albumin or postoperatively
using 5 percent human albumin and one liter of fresh frozen
plasma as substitution. Detection of anti-HLA antibodies
was performed by Luminex technology. Sera of patients were
tested by Lifecodes LSA Class I/II (Genprobe, Transplant
Diagnostics, Stamford, USA) single antigen bead assay to
identify anti-HLA antibody speciﬁcity and intensity.
2.4. Measurement of Anti-Measles Antibodies. Quantitative
measurement of anti-measles IgG antibodies was per-
formed in stored serum or plasma samples by an enzyme
immunoassay used in routine laboratory practice. Brieﬂy,
IgG antibodies speciﬁc for measles in the test sample bind
to the antigen (permanent simian kidney cells infected with
measles virus) or as control to noninfected cells and are
incubated at 37◦ for 1h. After completing 4 wash cycles, the
conjugate (anti-human IgG/POD) is added and incubated
for 1h. After washing, the substrate is added for 30min
at room temperature protected from light. Measurement is
performed at 450nm after adding of the stopping solution.
Evaluation is performed automatically in BEP III (Siemens,
Germany). A titer >150mU/l was deﬁned positive. Anti-
measles antibodies were measured in serum samples before
rituximab treatment, the day before transplantation and
during followup. In three patients, anti-measles antibodies
were determined at the beginning and at the end of a single
plasma exchange session. Furthermore, in two patients, anti-
measles antibodies were determined serially over a period of
∼3 years, respectively.
3. Results
3.1. Baseline Anti-Measles Antibody Titers. Baseline data and
treatment modalities are reported in Table 1.A l lp a t i e n t sJournal of Transplantation 3
Table 1: Patient characteristics.
Patient Age/Sex IVIG Blood group
Donor→Recipient Titer Plasma exchange
(before/after tx)
Immunoadsorption
(before/after tx)
14 2 f y e s A 2 → B1 : 4 4 / 0
24 5 f y e s B → O1 : 3 2 4 / 0
31 7 m n o A 1 → O1 : 3 2 3 / 1 4 / 0
42 3 m n o A 2 → O1 : 6 4 3 / 0
56 6 f n o A 2 → O1 : 8 2 / 0
66 4 f n o A 2 → O1 : 8 2 / 0
74 1 m n o A 1 → O 1:1024 3/0 11/3
86 3 m n o A 1 → O 1:1024 9/1
96 4 m n o A 1 → O 1:256 8/0
10 51m no B → A1 1:8 2/0
11 56 f no A1B → A1 1:128 4/0
12 48 f no A1B → A1 1:2 2/0
HLA antibodies
13 47m no HLA 11/9
14 47 f yes HLA 6/2
15 37m yes HLA 7/0
Age in years; sex: m: male, f: female. IVIG: intravenous immunoglobulin. Titer: in case of ABO-incompatible transplantation anti-A/B isoagglutinint i t e r s
beforestartofdesensitizationaregiven,andapheresiswasperformeduntilisoagglutinintiterswere1:4orlessonthedayofsurgery.Thenumberoftreatments
using plasma exchange or antigen-speciﬁc immunoadsorption either before kidney transplantation (before-tx) or after successful kidney transplantation is
given. Plasma exchange was usually performed with 5 percent albumin as replacement ﬂuid. Additionally, fresh frozen plasma was used in patient 3 for the
plasma exchange on the day before surgery and a plasma exchange 6 days after transplantation; in patient 14 for the plasma exchanges 2 and 4 days after
transplantation; in patient 2 on the day of surgery.
had detectable anti-measles antibodies (>150mU/l) before
starting desensitization therapy (mean 3238mU/l, median
2600mU/l, and range 560–8100mU/l). In two patients,
anti-measles antibodies were tested serially before and after
transplantation, in patient 6 six times over a period of 36
months, and in patient 5 seven times over a period of
32 months. Anti-measles antibodies remained stable over
this period with a standard deviation of 9% and 13%,
respectively.
3.2. Eﬀect of Apheresis on Antibody Titers. Overall, ABO
blood group antibodies and HLA antibodies were eﬀectively
reduced during the desensitization protocol using either
plasma exchange, antigen-speciﬁc immunoadsorption, or
both treatments.
Anti-measles antibody levels were measured in 3 patients
at the beginning and at the end of a single plasma ex-
change session. A single treatment reduced the antibody
concentration by 42%. Using plasma exchange, anti-measles
antibodies decreased signiﬁcantly in all patients (n = 7),
with reduction from a mean of 2399mU/l (median 1500;
range 730–7700mU/l) to a mean of 1710mU/l (median
1100; range 150–5800mU/l; P<0.05). This represented a
decrease of 40% after 2 to 7 plasma exchanges (Figure 1). In
two patients, anti-measles antibody titers were low at time of
transplantation, and in one patient, the antibody concentra-
tion decreased to nondetectable values immediately after the
plasma exchange session (Figure 2).
In patients using antigen-speciﬁc immunoadsorption,
only (n = 8) anti-measles antibody levels decreased slightly,
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Figure 1: Eﬀect of apheresis on reduction of anti-measles IgG anti-
bodies. Antibody titer reduction (in %) at time of transplantation
in comparison to the baseline values among patients using plasma
exchange either alone or in combination with antigen-speciﬁc
immunoadsorption (n = 7) or antigen-speciﬁc immunoadsorption
alone (n = 8). There was a mean reduction of 40% in the plasma
exchange group.
but without statistical signiﬁcance (mean antibody level
3973 versus 3751mU/l). All patients had highly protective
antibody levels at time of transplantation (Figure 2).
3.3. Eﬀect of Immunoglobulin Treatment. In four patients,
intravenousimmunoglobulinsweregivenaspartofthetreat-
ment protocol. In one patient treated with antigen-speciﬁc4 Journal of Transplantation
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Figure 2: Eﬀect of desensitization therapy on anti-measles IgG
antibody titers (mU/l). Anti-measles antibodies were measured
before desensitization therapy (“before”), the day before trans-
plantation (“tx”) and during followup (“after”). Patients were
analysed according to the used apheresis strategies: use of plasma
exchange either alone or in combination with antigen-speciﬁc
immunoadsorption (n = 7) or antigen-speciﬁc immunoadsorption
alone (n = 8). At the time of transplantation, antibody titers were
signiﬁcantly reduced in the plasma exchange group compared to
baseline (P<0.05).
immunoadsorption, anti-measles antibody level increased at
time of transplantation. The other three patients received
intravenous immunoglobulins either one to two weeks
before the start of plasma exchange (patient 14 and 15) or
two days before the last plasma exchange (patient 2). Among
patients using plasma exchange, anti-measles antibodies
were lowered more eﬀectively in those patients not receiving
intravenous immunoglobulins, although due to the small
number of patients without statistical signiﬁcance (47%
versus 29%, P>0.1). There were no diﬀerences in clinical
outcomes regarding infections between these patient groups.
3.4. Anti-Measles-Antibody Titers during Followup. During
followup (median 64 days after transplantation, range 26–
1114 days), all patients had protective immunity against
measles (n = 14, median 2950mU/l, and range 530–
7100mU/l). Anti-measles antibodies remained stable as
compared to baseline values or increased in most patients
after temporal reduction during desensitization therapy
despite immunosuppressive therapy.
4. Discussion
A decrease of vaccination rates and a lower herd immunity
have triggered recent outbreaks of measles in Germany and
other countries. New and more intense treatment strategies
utilizing apheresis techniques and increased immunosup-
pression might even further increase the infectious risk
for transplanted patients. Furthermore, the possibility of
atypical presentation of measles with nonspeciﬁc respiratory
or neurological symptoms has to be considered in immuno-
compromised patients [10, 11].
Patients born before the implementation of vaccination
against measles most likely had natural measles and lifelong
immunity. However, children and young adults born after
1970 who are unvaccinated or have received only one dose
of vaccine with suboptimal protection are at risk. In our
population, all 15 adult patients, including 3 patients born
after 1970, had protective levels of anti-measles antibodies
prior to transplantation and desensitization therapy. In con-
trast, in children receiving solid organ transplants, a lower
rate of protective antibody titers against measles (80%) and
other viruses [12] and loss of antibodies to measles after
transplantation in a signiﬁcant proportion of individuals
have been reported [13].
This limited degree of immunity against measles might
be further reduced when potent desensitization protocols
are used as, for example, in ABO-incompatible renal trans-
plantation. The eﬀect of therapeutic apheresis on speciﬁc
antibody levels against bacterial antigens has been investi-
gated only in small patient groups. Despite using antigen-
speciﬁc immunoadsorption with Glycosorb A/B columns,
several authors reported a signiﬁcant reduction of total IgG
and IgM [14, 15]. Antibodies against tetanus and diphtheria
protein antigens were not signiﬁcantly aﬀected. However,
antibodies against pneumococcus and haemophilus polysac-
charide antigens were signiﬁcantly reduced [14, 15]; in some
patients, antibody levels decreased even below the protective
threshold values.
Weextendtheseﬁndingsbyreportingtheeﬀectofplasma
exchange and antigen-speciﬁc immunoadsorption on the
levels of anti-measles antibodies. Plasma exchange signiﬁ-
cantly reduced anti-measles IgG titers, in 3/7 patients to low
values, and in one patient even below the detection threshold
immediately after the plasma exchange session. The eﬀect
of antigen-speciﬁc immunoadsorption was diverse and not
statistically signiﬁcant, although antibody levels decreased
in several patients. The reduction of anti-measles antibody
titers was merely transient, and anti-measles antibody levels
remained stable as compared to baseline values or increased
in most patients over time. However, it has to be considered
that antibody reduction might be more pronounced in
patients with preexisting low anti-measles-antibody titers
and/or intensive use of apheresis techniques. In this setting,
patients would be at high risk for posttransplant infection.
Therefore, a pretransplant booster vaccination might be use-
ful in patients with low titers.
In most protocols, intravenous immunoglobulins
(IVIGs) or cytomegalovirus immune globulin (CMVIg) has
been used as part of the desensitization therapy in com-
bination with plasma exchange and antigen-speciﬁc im-
munoadsorption. Although the exact immunosuppressive
mechanism is unknown, an immunomodulatory eﬀect
by replacing removed antibody and suppressing de
novo antibody production is speculated [5]. However,
preparation (CMVIg, several IVIG preparations), dosing,
and timing are highly variable (0.1g/kg after each plasma
exchange; 2g/kg after the ﬁnal plasma exchange; 0.5g/kg
1 or 5 days prior to transplantation using antigen-
speciﬁc immunoadsorption) [1, 3, 4, 6, 7, 16, 17], and
randomized trials are lacking. It should also be consideredJournal of Transplantation 5
that diﬀerent IVIG preparations contain blood group
antibodies in variable titers [18]. Because of uncertainties
about the mechanism and potential side eﬀects [16], we
and other groups have safely omitted routine application of
IVIGs in ABO-incompatible transplantation.
Despite immunomodulatory eﬀects, substitution with
intravenous immunoglobulins (IVIG) can restore the pro-
tective IgG pool in the ﬁrst weeks after transplantation,
as has been shown previously [15]. IVIG and fresh frozen
plasma contain a variety of protective antiviral antibodies
including anti-measles antibodies in varying concentrations.
As can be demonstrated in patient 1 using antigen-speciﬁc
immunoadsorption, application of IVIG can increase the
anti-measles antibody titer more than 100%. There was also
a trend that among patients using plasma exchange, anti-
measles antibodies were lowered less eﬀectively in those
patients receiving IVIG. However, in our study, IVIG was
used as part of the desensitization protocol and not as
substitution after completion of apheresis treatment. Re-
gardless of the use of IVIG, anti-measles antibodies were
signiﬁcantly lowered using plasma exchange as compared
to antigen-speciﬁc immunoadsorption. Fresh frozen plasma
was only used in three patients immediately before or after
transplantation. The impact on our results will likely be
limited, as the use of one liter of fresh frozen plasma will
not suﬃciently and long lasting restore the IgG pool. With a
half-life of ∼20 days for IgG, the increase of the anti-measles
antibody titers measured after transplantation (median 64
days) represents the endogenous production, rather than an
eﬀect of substitution with fresh frozen plasma or IVIG as
used in our protocol.
Anti-measles antibody titers were lowered temporarily
towards the detection limit only in those two patients using
plasma exchange with low anti-measles antibody titers at
start of desensitization therapy. However, in most patients,
antibody levels remained above the protective threshold and
substitution with IVIG will not be necessary.
5. Conclusions
Immunity against measles was detectable in all adult pa-
tients undergoing desensitization with plasmapheresis or
immunoadsorption plus rituximab but was temporarily
reduced at the time of transplantation. Anti-measles anti-
bodies remained detectable in all but one patients at time
oftransplantation.Currentdesensitizationdoesnotcompro-
mise protective immunity against measles permanently.
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